Dislipemia, obesidad e hipovitaminosis D en el Adulto mayor: ¿Tratamiento único?
Resumen
La dislipemia, aislada o como integrante de un cuadro multifactorial, afecta en gran medida a los adultos mayores. Similar característica se da en lo que atañe a la hipovitaminosis D, déficit que debe ser buscado activamente por el médico tratante Cuando la hipovitaminosis D es detectada, merece tratamiento de reposición del nutriente pues su carencia crónica y severa lleva a un hiperparatiroidismo secundario con todo el efecto deletéreo sobre la masa ósea. Ambos cuadros, dislipemia y déficit de vitamina D, tienen directa interrelación uno con otro a punto tal que la terapia del primero influye en el segundo y viceversa, aunque por mecanismos diferentes. De la revisión de la literatura internacional se desprende que el tratamiento de la dislipemia (aislada, como parte de un cuadro de sobrepeso/obesidad) aumenta los niveles plasmáticos de vitamina D. Para el adulto mayor este aumento implica una serie de cambios como: mejoría de la hipertensión y/o de la respuesta a su terapia farmacológica; aumento de la fuerza muscular, particularmente a nivel de la cintura pelviana; disminución consiguiente en la incidencia de caídas y menor prevalencia de fracturas óseas, aumento de la inmunidad y prevención en la aparición de tumores varios, etc. El aumento de la vitamina D plasmática parece ser mayor con algunas drogas hipolipemiantes, y de estas, la rosuvastatina tendría el mayor efecto. ...
Palabras clave
Texto completo:
20-29Referencias
Dorland – Diccionario Enciclopédico Ilustrado de Medicina. McGraw Hill Interamericana. 29° Edición, España, 2000. T. I, pág. 621.
Griera Borrás JL, Contreras Gilbert J. ¿Existe el obeso sano? Endocrinol Nutr. 2013; 1-5.
Ventriglia I. Obesidad en el adulto. En Rubinstein A, Terrasa S. Medicina Familiar y Ambulatoria. 2° Edición, Editorial Médica Panamericana, Buenos Aires, Argentina. 2006. Cap. 225, pág. 1707 y ss.
Botargues M. Hipercolesterolemia. En Rubinstein A, Terrasa S. ibid.
Bordelon P, Ghetu MV, Langan R. Recognition and managment of vitamin D deficiency. American Family Physician 2009; 80(8): 841-6.
Hanley DA et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ • September 7, 2010; 182(12): 610-8.
Vanlint M. Vitamin D and obesity. Nutrients 2013; 5 (3): 949–56.
González Molero I, Rojo Martínez G, Morcillo S et al. Hypovitaminosis D and incidence of obesity: a prospective study. European Journal of Clinical Nutrition 2013; 67(6) 680-2.
Mawer EB et al. The distribution and storage of vitamin D and its metabolites in human tissues. Clinical Science 1972; 43 (3): 413–43.
Cipriani C, Pepe J, Piemonte S et al. Vitamin D and Its Relationship with Obesity and Muscle. International Journal of Endocrinology 2014; Article ID 841248.
Candido FG, Bressan J. Vitamin D: link between osteoporosis, obesity and diabetes. Int. J. Mol. Sci. 2014; 15: 6569-6591.
Gutiérrez-Medina S, Gavela-Pérez T, Domínguez-Garrido MN et al. High prevalence of vitamin D deficiency among spanish obese children and adolescents. An Pediatr (Barc) 2014; 80(4):229-35.
Glossman HH, Blumthaler M. Does rosuvastatin increase serum levels of 25-hydroxy-vitamin D? Dermato-Endocrinology 2012: 4(1); 2–7.
Schreier L, Berg G. Alteraciones del metabolismo de los lípidos. En Lerman J, Iglesias R. Enfoque integral del síndrome metabólico. Ed. Intermédica, Buenos Aires, Argentina, 2009. Cap. 8, pág. 91 y ss.
Nissen S, Tuzcu E, Schoenhagen P et al. Statin therapy, LDL colesterol, C reactive protein and coronary artery disease. NEJM 2005; 352: 29-38.
Stalenhoef A, Ballantyne C, Sarti C et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the Comet study. Eur Heart J 2005; 26: 2664-72.
Targher G, Bertolini L, Scala L et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutrition Metabolism and Cardiovascular Diseases 2007; 17 (7): 517–524.
Ding C, Parameswaran V, Blizzard L, Burgess J, Jones G. Not a simple fat-soluble vitamin: changes in serum 25-(OH)D levels are predicted by adiposity and adipocytokines in older adults. Journal of Internal Medicine 2010; 268 (5): 501–10.
Earthman CP, Beckman L M, Masodkar K, Sibley S D. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. International Journal of Obesity 2012; 36 (3): 387-96.
Konradsen S, Ag H, Lindberg F, Hexeberg S, and Jorde R. Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. European Journal of Nutrition 2008; 47 (2): 87–91.
Souberbielle JC. Vitamina D. Anejo Producciones SA, Buenos Aires, Argentina, 2012. Primera Edición, Cap. 1, pág. 14.
Qin XF, Zhao LS, Chen WR, Yin DW, Wang H. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: A randomized placebo-controlled trial. Clin Nutr. 2014 May 2.
Ponda MP, Dowd K, Finkielstein D, Holt PR, Breslow JL. The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2012; 32(10): 2510-5.
Asemi Z, Hashemi T, Karamali M, Samimi M, Esmaillzadeh A. Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. Am J Clin Nutr. 2013; 98(6):1425-32.
Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011; 50(4): 303-12.
Bevaqua A. Vitamina D en la tercera edad. Revista de la Asociación Médica de Bahía Blanca 2015; 25 (1): 8-15
McKenna MJ, Freaney R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporosis Int 1998; 8 (2): 53-56.
Eastwood JB, de Wardener HE, Gray RW et al. Normal plasma 1,25(OH)2 Vitamin D concentrations in nutritional osteomalacia. Lancet 1979; 1: 1377-1378.
Holick MF, Chen TC, Lu Z et al. Vitamin and skin physiology: a D-lightfulstory. J Bone Miner Res 2007; 2 (2): 28-33.
Daly RM. Independent and Combined Effects of Exercise and Vitamin D on Muscle Morphology, Function and Falls in the Elderly. Nutrients 2010; 2: 1005-1017.
Andrade Chagas CE, Borges MC, Martini LA, Macedo Rogero M. Focus on Vitamin D, Inflammation and Type 2 Diabetes. Nutrients 2012; 4: 52-67.
Hanley DA, Cranney A, Glenville Jones et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010; 182(12): 610-618.
Paul G, Alcorn JF et al. Vitamin D and Asthma. Am J Respir Crit Care Med 2012; 185 (2): 124–132.
Vieth R. Vitamin D supplementation, 25 hydroxivitamin D concentrations and safety. AM J Clin Nutr 199; 69: 842-856.
Alshahrani F, Aljohani N. Vitamin D: Deficiency, Sufficiency and Toxicity. Nutrients 2013; 5: 3605-3616.
Holick MF, Biancuzzo RM, Chen TC et al. Vitamin D2 is as effective as Vitamin D3 in maintaining concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008; 93: 677-81.
Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than Vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89: 5387-91.
Hathcock JN, Shao A, Vieth R et al. Risk assessment for Vitamin D. Am J Clin Nutr 2007; 85: 6-18.
Piñeiro Corrales G, Vázquez López C, Álvarez Payero M. Effect of pharmacologic treatment of the nutritional status of neurologic patients. Nutr Hosp. 2014; 29 (2):47-56.
van Orten-Luiten AC, Janse A, Dhonukshe-Rutten RA, Witkamp RF. The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies. Drugs Aging. 2014; 31(2):111-23.
Glossmann HH, Blumthaler M. Does rosuvastatin increase serum levels of 25-hydroxy-vitamin D? Dermatoendocrinol. 2012 1; 4(1):2-7.
Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. Cardiovasc Pharmacol Ther. 2012; 17(4):382-6.
Yavuz B, Ertugrul DT, Cil H et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009; 23(4):295-9.
Grimes DS. Statins and vitamin D: editorial to: "Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?" by Bunyamin Yavuz et al. Cardiovasc Drugs Ther. 2009; 23(4):261-2.
Toth PP. An update on the benefits and risks of rosuvastatin therapy. Postgrad Med. 2014; 126(2):7-17.
Guthrie RM. How safe is aggressive statin therapy? Prog Cardiovasc Nurse 2006; 21(3): 140-145.
Mc Kenney JM. Efficacy and safety of rosuvastatin in treatment of dislipemia. Am J Health Syst Pharm 2005; 62(10): 1033-47.
Stein E. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler Suppl 2002; 2(4): 19-23.
Kei A, Liberopoulos EN, Mikhailidis DP, Elisaf M. Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. Int J Clin Pract. 2013; 67(5):412-9.
Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisof M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega 3 fatty acidon serum Vitamin D levels. J Cardiovasc Pharmacol Ther 2012; 17 (4): 382-6.
McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002; 22(7):814-22.
Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996;129(1):42-49.
van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001;134(2):409-17.
Quin XF, Zhao LS, Chen WR, Yin DW, Wang H. Effects of vitamin D on plasma lipid profiles in statin treated patients with hypercholesterolemia: a randomized placebo control trial. Clin Nutr 2014; 14: 261.
Cutillas-Marco E, Prosper AF, Grant WB, Morales-Suárez-Varela MM. Vitamin D status and hypercholesterolemia in Spanish general population. Dermatoendocrinol. 2013; 5(3):358-62.
Ware W R. The JUPITER lipid lowering trial and vitamin D. Is there a connection? Dermato-Endocrinology 2010; 2 (2): 50-4.
Grimes D S. Editorial to: “Increased Levels of 25 Hydroxyvitamin D and 1,25-Dihydroxyvitamin D after Rosuvastatin Treatment: A Novel Pleiotropic Effect of Statins?” by Bunyamin Yavuz et al. Cardiovasc Drugs Ther 2009; 23:261–2.
Holick M F. The statin D-lemma. Dermato-Endocrinology 2012; 4(1): 10–1.
Enlaces refback
Copyright (c) 2019 Alejandro Bevaquq
Asociación Médica de Bahía Blanca - Castelli 213 - B8000AIE Bahía Blanca - Buenos Aires - Argentina - https://www.ambb.org.ar